72 results about "Orally disintegrating tablet" patented technology

A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

The invention belongs to the technical field of medicines, and particularly relates to a melogabalin besylate orally disintegrating tablet coated with powder. The powder-coated melogabalin besylate orally disintegrating tablet provided by the invention has good wet stability, effectively masks the bitter taste of the raw material medicines, obviously improves the taste, has good dissolution behavior, shows extremely rapid dissolution in key media, is beneficial to the absorption of melogabalin besylate by the body, and can be used for preparing the oral disintegrating tablet for treating melogabalin besylate. The melogabalin besylate orally disintegrating tablet provided by the invention has a good application prospect.

The application belongs to the technical field of pharmaceutical preparations, and specifically provides a kind of indobufen freeze-dried oral disintegrating tablet and a preparation method thereof.The freeze-dried oral disintegrating tablet contains indobufen and xanthan gum, and the freeze-dried oral disintegrating tablet can be obtained by freeze-drying technology after the above components are prepared into a suspension.The freeze-dried oral disintegrating tablet provided by the application has the technical characteristics of good properties, complete demolding, high drug loading, good content uniformity, rapid disintegration and rapid dissolution, and can meet the needs of rapid anti-platelet therapy in acute thrombosis events.

1. Name of the product in this design: Pharmaceutical Packaging Box (Salbutamol Sulfate Orally Disintegrating Tablets for Children). 2. Purpose of this design: This design is used for packaging salbutamol sulfate orally disintegrating tablets. 3. The key design features of this product are the combination of pattern and color. 4. The image or photograph that best illustrates the design's key points: a 3D model. 5. The design for which protection is sought includes color.

The present application belongs to the technical field of oral solid preparation, and particularly relates to a mosapride citrate orally disintegrating tablet and a preparation method thereof. Raw and auxiliary materials comprise mosapride citrate, a filling agent, a disintegrating agent, a glidant, a lubricant and a flavoring agent. The present application screens and optimizes the auxiliary material formula, adopts dry granulation, optimizes the preparation process, improves the compressibility and fluidity of the material, saves energy, improves the production quality and stability, makes the prepared orally disintegrating tablet disintegrate rapidly, has excellent taste, greatly improves the medication compliance of patients, simultaneously improves the drug dissolution and improves the bioavailability. In addition, compared with other types of solid oral preparations of the product, the mosapride citrate orally disintegrating tablet is particularly suitable for the elderly and patients with difficulty in swallowing, and provides convenience in special and urgent situations such as lack of drinking water for taking medicine.

The invention discloses a preparation method for prolonging the validity period of erythromycin ethylsuccinate orally disintegrating tablets. The preparation method comprises the following steps: sequentially putting low-substituted hydroxypropyl cellulose, microcrystalline cellulose, aspartame, carboxymethyl starch sodium and polyvinylpolypyrrolidone into a wet granulation mixer, covering with a cover, starting equipment, carrying out low-speed dry mixing for 3 minutes, slowly adding low-concentration hydroxypropyl methylcellulose slurry from a feed port of a pot cover, and carrying out low-speed wet mixing for 3 minutes; stopping the machine, opening the cover, scraping powder on the inner surface of the pot cover and the periphery of the inner side of the pot by using a clean scraper, adding erythromycin ethylsuccinate raw materials, covering the cover, starting equipment, carrying out low-speed wet mixing for 3 minutes, and carrying out high-speed wet mixing for 2 minutes. By improving the medicine production process, the stability and durability of the medicine are improved, so that the validity period of the medicine is prolonged, and meanwhile, the effectiveness and safety of the medicine can still be kept within the prolonged validity period.

The invention discloses an orally disintegrating tablet and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations. The orally disintegrating tablet comprises 0.5-30 wt% of an active component, 25-35 wt% of an adhesive, 25-65 wt% of a filler and 1-10 wt% of a suspending aid, the active component comprises an antipsychotic raw material medicine and / or an antiepileptic raw material medicine. The void ratio of the orally disintegrating tablet is controlled to be 40-90%, even if the active ingredient is a low-solubility raw material medicine, the orally disintegrating tablet also has the fluffy feeling like puffed food, good taste and pleasant experience, meanwhile, the provided orally disintegrating tablet enables the medicine to be rapidly released in the oral cavity, the disintegration time in the oral cavity is shorter than 5 s, and the orally disintegrating tablet is suitable for oral administration. Compared with the oral cavity disintegration time of about 20s of disintegrating tablets and the oral cavity disintegration time of about 15s of oral soluble films in the prior art, the tablet has remarkable advantages, improves the compliance of patients, and greatly reduces the possibility of Tibetan medicine and vomiting of the patients especially for patients with dysphagia.

The application belongs to the technical field of medicine, and particularly relates to a kind of opicapone oral disintegrating tablets and a preparation method thereof.The active component of the opicapone oral disintegrating tablet is opicapone, and the components are as follows according to weight percentage: opicapone 15-25%; filler 60-70%; glidant 1-4%; lubricant 1-4%; first disintegrating agent 2-6%; and second disintegrating agent 2-6%, wherein the first disintegrating agent and the second disintegrating agent are different, and preferably, the weight content of the opicapone is 15-20%.The opicapone oral disintegrating tablet of the application is suitable for the adjuvant therapy of levodopa / carbidopa, has a fast disintegration rate, stable product quality, does not need to be taken with water, and has strong patient compliance; in addition, the preparation process of the opicapone oral disintegrating tablet of the application is simple, has low cost, and is suitable for mass production.

The invention discloses a quick-acting heart-saving freeze-dried orally disintegrating tablet and a preparation method thereof, and relates to the technical field of medicines, the quick-acting heart-saving freeze-dried orally disintegrating tablet is prepared from the following materials through freeze drying: a ligusticum wallichii extract, a borneol clathrate compound, a freeze-dried proppant, and an optional sweetening agent and / or thickening agent, the borneol clathrate compound is a clathrate compound prepared from cyclodextrin or a derivative thereof through a clathration technology. According to the freeze-dried orally disintegrating tablet and the preparation method thereof, the inclusion compound of the borneol and the cyclodextrin derivative is prepared firstly, then the inclusion compound and other raw and auxiliary materials are prepared into the freeze-dried orally disintegrating tablet according to a specific process, the stability of the borneol content in a final product can be effectively guaranteed, and cyclodextrin or the cyclodextrin derivative is selected from at least one of beta-cyclodextrin, hydroxypropyl-beta-cyclodextrin and sulfobutyl-beta-cyclodextrin. Meanwhile, the absolute ethyl alcohol for dissolving the borneol is removed during preparation of the inclusion compound, a special freeze dryer is not needed, the safety problem of equipment operation is avoided, and the production cost is reduced.

The application provides a butylphthalide sublingual tablet and a preparation method thereof, wherein the butylphthalide sublingual tablet contains the following components by weight percentage based on 100% of the total weight of the butylphthalide sublingual tablet: 10%-25% of an active substance, 10%-40% of an emulsifier, 10%-75% of an excipient, 0.2%-2% of a binder, 1%-30% of a sweetening agent, and 0.1%-2% of a fragrance agent; and the active substance is butylphthalide or a butylphthalide derivative. The application does not need to add a disintegrating agent, the auxiliary materials used are water-soluble, and the amount is small, so that the preparation can be rapidly disintegrated in the oral cavity without grit feeling, thereby overcoming the slow disintegration in the oral cavity and grit feeling of the oral disintegration tablet prepared by using a direct compression method.

The present invention discloses a device for measuring the disintegration time limit of a fully automatic orally disintegrating tablet, belonging to the technical field of measuring the time limit of orally disintegrating tablets. It includes a constant temperature water bath disintegration device, on the surface of which a reciprocating direct drive immersion module is configured. The output end of the reciprocating direct drive immersion module is assembled with a standard sieve basket to drive the standard sieve basket to perform reciprocating lifting movements in the vertical direction. A transparent observation water bath cylinder for storing constant temperature water is configured at the position directly below the up and down lifting of the standard sieve basket. Through a suspension mechanism and an optical displacement detection system based on force feedback, objective and continuous monitoring of the disintegration process of the orally disintegrating tablet is realized, and the disintegration state that is difficult to judge by the naked eye in the prior art, especially in the case of turbid solution or adhesion, is converted into a continuously measurable signal, overcoming the problems of relying on subjective experience and being easily interfered by observation conditions in the prior art.

The invention discloses a briracetam orally disintegrating tablet and a preparation method thereof, and belongs to the technical field of biological medicines. The briracetam orally disintegrating tablet is prepared from the following components in parts by mass: 10 to 50 parts of a briracetam cyclodextrin inclusion compound, 10 to 87 parts of a filling agent, 1 to 20 parts of a disintegrating agent, 1 to 10 parts of a lubricating agent and 1 to 10 parts of a flavoring agent. According to the preparation method disclosed by the invention, the defect of poor flowability of the briracetam is effectively improved by a process of firstly preparing the cyclodextrin inclusion compound of the briracetam and then pressing the inclusion compound into the tablet; performance inspection on the tablets shows that the tablets have the characteristic of rapid disintegration accidentally, and the stability is remarkably improved.

The invention relates to a brexpiprazole orally disintegrating tablet and a preparation method thereof. The invention provides the brexpiprazole-containing orally disintegrating tablet. The tablet has the advantages of excellent disintegrating property, good taste, no hard core and excellent storage stability; specifically, the orally disintegrating tablet provided by the invention comprises the following raw materials in addition to mannitol, low-substituted hydroxypropyl cellulose, hydroxypropyl methyl cellulose, microcrystalline cellulose, corn starch, sucralose, sodium stearyl fumarate and magnesium stearate, good friability (less than or equal to 0.3%) of the tablet under low hardness is ensured; moreover, the use amount of L-HPC is reduced (less than 5%), and L-HPC is supplemented into mannitol, so that the taste advantage of mannitol is more prominent on the basis of ensuring excellent disintegration; in addition, a small amount of corn starch is added, so that the problem of low content of the raw materials in the mixing process is solved. In addition, the invention further provides a preparation method which is simple in preparation process and high in production efficiency, and the problems that the brexpiprazole is low in proportion, poor in content uniformity and unqualified in dissolution curve are effectively solved.

The present invention relates to an orally disintegrating tablet manufactured by a direct compression method comprising paroxetine or pharmaceutically acceptable salts thereof, at least one disintegrant, at least one diluent, at least one lubricant, and one or more pharmaceutically acceptable excipients. The orally disintegrating tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. The present invention also relates to the process for preparing the said solid pharmaceutical composition.

The application discloses a kind of meloxicam benzenesulfonic acid oral disintegration tablets and preparation method thereof, belong to pharmaceutical preparation technical field, the oral disintegration tablet includes granule / powder A, granule / powder B and auxiliary material;Wherein, the granule / powder A includes: meloxicam benzenesulfonic acid, mannitol, antioxidant, stabilizer, first binder and first disintegrating agent;The antioxidant is butylated hydroxyanisole, and the stabilizer is tartaric acid and / or magnesium metasilicate aluminum;The granule / powder B includes: filler, mannitol, second binder and second disintegrating agent;The auxiliary material includes third disintegrating agent, potassium acetylsulfanate and magnesium stearate.The application is by adjusting tartaric acid, butylated hydroxyanisole, magnesium metasilicate aluminum and the matching of filler, adjusts granulation mixing mode and changes tabletting tablet type, so that the related substance of meloxicam benzenesulfonic acid oral disintegration tablet increases significantly slower, disintegration is significantly faster, solve the technical problem existing in prior art.

Disclosed is a dry powder oral formulation that includes an active pharmaceutical ingredient (API), a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation. Also disclosed are an excipient composition in absence of an API and methods of making and using the formulations and compositions. Also disclosed is a chewable, swallowable, and / or orally disintegrating tablet comprising an API, a lecithin powder, a galactomannan, one or more sweetening agents, one or more flavoring agents and an organic acid in a pharmaceutically acceptable preparation.

The invention provides an iron protein succinate orally disintegrating tablet and a preparation method thereof, and the iron protein succinate orally disintegrating tablet comprises the following components in parts by weight: 35-45 parts of iron protein succinate, 15-25 parts of trehalose, 25-35 parts of mannitol, 5-7 parts of sodium bicarbonate, 0.5-1.5 parts of polysorbate 80, 2-4 parts of strawberry essence, 0.5-1.5 parts of sucralose, and 8-12 parts of glycine. According to the freeze-dried orally disintegrating tablet disclosed by the invention, a skeleton is self-assembled through a main drug, the skeleton is dissolved through alkaline activation protein iron succinate, a three-dimensional net-shaped skeleton is self-assembled through hydrophobic interaction in a freeze-drying process, a gelatin skeleton is not needed for supporting, and the safety is improved; trehalose and mannitol synergistically regulate the porosity, so that the skeleton is light and crisp and can be quickly disintegrated, the ice crystal damage is reduced, and no fragmentation is caused in the transportation process. In addition, the freeze-dried orally disintegrating tablet has good taste and stability, is convenient to carry, improves patient compliance, is free of animal-derived component gelatin, reduces allergy risk, is suitable for children to take, and has good development prospects.

To provide an orally disintegrating tablet that exhibits good dissolution behavior even when a coating layer is applied to mask the bitter taste, and is of a size that is easy to pick up with your fingers. [Solution] The problem is solved by an orally disintegrating tablet containing granules in which a coating layer is provided on a core particle comprising rupatadine or a salt thereof and at least one additive selected from the group consisting of excipients, disintegrants, and binders, characterized in that the mass is 180 to 300 mg.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

An orally disintegrating tablet of amlodipine for oral administration comprising: a) amlodipine or pharmaceutically acceptable salts thereof, is present in an amount ranging from 2 to 10% w / w; b) at least one diluent; c) at least one disintegrant is present in the range from 1 to 10% w / w; d) at least one lubricant is present in the range from 0.2 to 7% w / w; e) at least one non-nutritive sweetener is present in the range from 0.1 to 7% w / w; f) at least one or more pharmaceutically acceptable excipients; wherein the ratio of combination of diluents to disintegrant is in the range from 15:1 to 40:1; and wherein orally disintegrating tablet is stable for at least three months under storage conditions of 25°C / 60% RH and 40°C / 75% RH.

To provide methods for producing an orally disintegrating tablet that has sufficient hardness to prevent the tablet from cracking during transportation and the handling by healthcare professionals and patients while maintaining rapid disintegration.SOLUTION: The method for producing an orally disintegrating tablet according to an embodiment of the present invention comprises a fluidized bed granulation by spraying or dropping onto an additive a liquid containing hydroxypropyl cellulose having a viscosity of 150 mPa s or more and 400 mPa s or less in a 2% aqueous solution at 20°C. The liquid containing hydroxypropyl cellulose may also be sprayed or dropped onto the additive so that the content of hydroxypropyl cellulose is 0.2 wt.% or more and 5 wt.% or less when the orally disintegrating tablet is 100 wt.%.SELECTED DRAWING: Figure 1

To provide an orally disintegrating tablet containing apixaban that maintains its disintegration properties even after storage. [Solution] A pharmaceutical composition containing the following components (a) and (b). (a) Apixaban or its salt or solvate (b) D-mannitol characterized by having a D90 of 200-400 μm

The invention relates to a pimavanserin orally disintegrating tablet as well as a preparation method and application thereof. The pimavanserin orally disintegrating tablet comprises pimavanserin or a salt thereof with unimodal particle size distribution, a disintegrating agent, a filling agent, a flavoring agent, a lubricating agent and a flow aid. The preparation method comprises four steps of API refining, premixing, total mixing and tabletting. The orally disintegrating tablet is especially suitable for Parkinson's disease psychosis with the following symptoms: (1) swallowing is difficult, and the tablet cannot be taken with water; and / or (2) the compound is sensitive to bitter taste and has a Tibetan medicine behavior; and / or (3) diabetes combined with Parkinson's disease psychosis.

The invention discloses a fenerenone orally disintegrating tablet and a preparation method thereof. The fenerenone orally disintegrating tablet disclosed by the invention is prepared from the following components in parts by mass: 10 to 35 parts of fenerenone, 1 to 20 parts of adhesive, 1 to 30 parts of skeleton agent, 0.01 to 5 parts of surfactant and 0.01 to 5 parts of flavoring agent. The preparation method comprises the main steps of liquid preparation, filling, freeze-drying and the like. The finerenone orally disintegrating tablet prepared by adopting the preparation prescription and the preparation method disclosed by the invention is uniform in color, smooth and flat in surface, neat in edge, free of melting and collapse and easy to package and transport; the dissolvability is greatly improved, the dissolvability can be quickly exerted after the dissolvability enters the gastrointestinal tract, the irritation to the digestive tract mucosa is small, and the adverse reaction caused by the irritation of the medicine is reduced.

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

A rapidly-orodispersible dosage form comprising a porous, bound-powder matrix and one or more internal cavities is provided, as well as three-dimensional printing methods for making the same. Each internal cavity is configured to contain one or more payloads, particularly pharmaceutical medicaments, while isolating the payloads from the external environment outside of the dosage form. Each payload can be contained within its cavity in its native form without having to be combined with the bound-powder matrix or binding liquid. Dosage forms can disintegrate in water or saliva in less than two minutes, independently of the payload(s) or medicament(s) contained within. The dosage forms can be formed as unitary tablets, or as two-piece tablets comprising a container body and a lidding body that are secured together to isolate the one or more cavities and their payloads inside.

The present disclosure provides a novel, palatable pharmaceutical composition in the form of taste-masked 2,4,6-trifluoro-N-[6-(1-methylpiperidine-4-carbonyl)-2-pyridyl]benzamide hemisuccinate and an orally disintegrating tablet comprising the same. The taste-masked orally disintegrating tablet of the present invention significantly reduces the strong bitter taste of lasmiditan and allows administration of this product form to migraine patients, particularly pediatric patients and patients who suffer from nausea due to migraine attacks.